In
the previous studies it has been hypothesized that low levels of the
enzyme thymidylate synthase (TS ) is probably observed in those patients
for whom the drug pemetrexed help , but the results were , at least,
inconclusive and sometimes contradictory.
Studies
in the University Cancer Center in Colorado and recently published in
the publication Journal of Thoracic Oncology, give an explanation of why
: only in conjunction with a high level of the second enzyme (
folilpoliglyutamat synthetase ) FPGS, low level vehicle allows us to
predict the response to pemetrexed in patients with malignant pleural mesothelioma .
"
There is hope that oncologists were able to check on the patient's
levels of TS and FPGS enzymes and thus detect whether the patient
treated pemetrexed or more appropriate is another type of treatment ," -
says first author , Daniel K. Christoph , MD Sciences,
oncologist West German Cancer Center , working postdoctoral as an
international research scientist in the laboratory researcher University
of Colorado Cancer Center MD Fred Hirsch .
Pemetrexed acts by inhibiting the enzyme TS , which requires cancer cells to replicate their DNA. Thus,
it stands to reason that those tumors that have already TC level
already low , the drug will have the greatest impact : TC practically
blocking residual cancer cells stop the synthesis of new DNA .
At
the same time , Christophe and his colleagues tested 84 cases of
mesothelioma in which treatment patients were drug pemetrexed , and
found that only the combination of low levels of TC with simultaneously
high FPGS allows us to predict a patient's response to this medication .
The study was also able to explain the mechanism by which FPGS improves the clinical efficacy of pemetrexed :
"
The high level of FPGS enables pemetrexed to stay longer inside the
cell , allowing the drug to act against vehicle for a longer time " -
continues to Christophe . From
the cases investigated in patients with low and high TS FPGS
increasingly respond to treatment with pemetrexed and their life
expectancy was longer after treatment .
According
to Kristof , the current study is the material preclinical work needed
to confirm the results of studies predicting the effectiveness and
impact of TC FPGS for patients with mesothelioma . Further
research and monitoring of data of these biological markers may allow
their wide use in predicting the effectiveness of treatment of patients
drug pemetrexed .
Subscribe to:
Post Comments (Atom)
Post a Comment